Advances in Alcohol Use Disorder Treatment, Volume 178 in the International Review in Neurobiology series, presents a comprehensive exploration of emerging therapies and approaches in the field. Topics in this new release include Introduction: Current Treatments, Oxytocin and Vasopressin, Neuroactive steroids, Pharmacological activators of ALDH2, Anti inflammatories and mesenchymal stem cells, Sodium oxybate, Psychedelic compounds, Cannabinoids, Environmental Enrichment, Animal models and translational challenges, GABAergic compounds, and Ghrelin system and GLP-1.
1. Chapter One: Introduction: Approved treatments for alcohol use disorder by regulatory agencies - p. 2 2. Chapter Two: Role of oxytocin and vasopressin in alcohol use disorder - p. 24 3. Chapter Three: Emerging evidence for pregnane steroid therapeutics for alcohol use disorders - p. 60 4. Chapter Four: The CRF/Urocortin systems as therapeutic targets for alcohol use disorders - p. 98 5. Chapter Five: Pharmacological activators of ALDH2: A new strategy for the treatment of alcohol use disorders - p. 154 6. Chapter Six: Mesenchymal stem cells as a promising therapy for alcohol use disorder - p. 180 7. Chapter Seven: Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence - p. 215 8. Chapter Eight: Ayahuasca for the treatment of alcohol use disorder - p. 284 9. Chapter Nine: Cannabinoid for alcohol use disorder - p. 302 10. Chapter Ten: Environmental enrichment and complementary clinical interventions as therapeutic approaches for alcohol use disorder in animal models and humans - p. 324 11. Chapter Eleven: Animal models for studying therapeutic targets and treatments for alcohol use disorder - p. 354 12. Chapter Tweleve: GABAergic compounds for the treatment of alcohol use disorder - p. 384 13. Chapter Thirteen: Ghrelin system and GLP-1 as potential treatment targets for alcohol use disorder - p. 397
Advances in Alcohol Use Disorder Treatment, Volume 178 in the International Review in Neurobiology series, presents a comprehensive exploration of emerging therapies and approaches in the field. Topics in this new release include Introduction: Current Treatments, Oxytocin and Vasopressin, Neuroactive steroids, Pharmacological activators of ALDH2, Anti inflammatories and mesenchymal stem cells, Sodium oxybate, Psychedelic compounds, Cannabinoids, Environmental Enrichment, Animal models and translational challenges, GABAergic compounds, and Ghrelin system and GLP-1.
1. Chapter One: Introduction: Approved treatments for alcohol use disorder by regulatory agencies - p. 2 2. Chapter Two: Role of oxytocin and vasopressin in alcohol use disorder - p. 24 3. Chapter Three: Emerging evidence for pregnane steroid therapeutics for alcohol use disorders - p. 60 4. Chapter Four: The CRF/Urocortin systems as therapeutic targets for alcohol use disorders - p. 98 5. Chapter Five: Pharmacological activators of ALDH2: A new strategy for the treatment of alcohol use disorders - p. 154 6. Chapter Six: Mesenchymal stem cells as a promising therapy for alcohol use disorder - p. 180 7. Chapter Seven: Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence - p. 215 8. Chapter Eight: Ayahuasca for the treatment of alcohol use disorder - p. 284 9. Chapter Nine: Cannabinoid for alcohol use disorder - p. 302 10. Chapter Ten: Environmental enrichment and complementary clinical interventions as therapeutic approaches for alcohol use disorder in animal models and humans - p. 324 11. Chapter Eleven: Animal models for studying therapeutic targets and treatments for alcohol use disorder - p. 354 12. Chapter Tweleve: GABAergic compounds for the treatment of alcohol use disorder - p. 384 13. Chapter Thirteen: Ghrelin system and GLP-1 as potential treatment targets for alcohol use disorder - p. 397
